Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541142 | 0.91 | BRD4 (0.40) | HRH3MEN1KMT2AATMBRD4 | |
| SCHEMBL22541229 | 0.88 | BRD4 (0.47) | HRH3MEN1KMT2AATMBRD4 | |
| SCHEMBL22541185 | 0.87 | BRD4 (0.41) | HRH3MEN1KMT2AATMBRD4 | |
| SCHEMBL22541191 | 0.86 | BRD4 (0.48) | HRH3BRD4 | |
| SCHEMBL22541164 | 0.85 | BRD4 (0.43) | HRH3MEN1KMT2AATMBRD4 | |
| SCHEMBL22541279 | 0.84 | BRD4 (0.42) | HRH3BRD4 | |
| SCHEMBL15526019 | 0.80 | BRD4 (0.48) | BRD4 | |
| SCHEMBL22541216 | 0.79 | BRD4 (0.41) | BRD4MGLL | |
| SCHEMBL24322009 | 0.79 | L3MBTL1 (0.44) | MEN1KMT2A | |
| SCHEMBL22547923 | 0.79 | BRD4 (0.47) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162228-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162228-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMA6, PSMC2 | HRH3 4398/4885MEN1 1361/4885KMT2A 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.